New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022

Abstract

Pancreatic cancer is the sixth leading cause of cancer-related death in China. It is characterized by high malignancy and concealment at early stages. More than 80% of patients have progressed to advanced stages at the time of diagnosis, and missed the opportunity of surgical resection. Pancreatic cancer patients who have successfully received surgical resection are at a high risk of metastasis, and the 5-year survival rate is only 15%-20%. Unlike other types of cancer, radiotherapy, chemotherapy and immunotherapy do not work well for pancreatic cancer, and the research in molecular subtyping and precision medical therapy technology is also slow. It is an urgent need to devote more clinical medical resources and transfer high-quality scientific research achievements to improve the prognosis of patients. The year 2022 is a year of profound accumulation in the field of translational pancreatic cancer research, witnessing the generation of the first small-molecule drug targeting KRASG12D and the clinical application of personalized T-cell receptor engineered T (TCR-T) cell therapy, as well as other advances in basic fields such as pathogenesis, molecular mechanism, metabolic immune microenvironment, and clinical fields such as early diagnosis, surgical treatment, radiation therapy, chemotherapy and immunotherapy. Here we reviewed the latest progress in research, diagnosis and treatment of pancreatic cancer in 2022.

Keywords

• |pancreatic cancer|basic research|clinical research